Characteristics of 127 patients with advanced rare cancers treated with pembrolizumab
| All patients (n=127) | |
| Age at enrollment, years | |
| Median (range) | 56 (22–84) |
| Sex, n (%) | |
| Male | 68 (54) |
| Female | 59 (46) |
| ECOG performance status, n (%) | |
| 0 | 15 (12) |
| 1 | 112 (88) |
| Number of prior therapies, n (%) | |
| ≤2 | 78 (61) |
| >2 | 49 (39) |
| Cohort, n | |
| (1) Squamous cell carcinoma of the skin | 19 |
| (2) Small cell malignancies of non-pulmonary origin | 11 |
| (3) Adrenocortical carcinoma | 15 |
| (4) Medullary renal cell carcinoma | 4 |
| (5) Carcinoma of unknown primary | 22 |
| (6) Penile carcinoma | 3 |
| (7) Vascular sarcoma | 7 |
| (8) Germ cell tumor | 12 |
| (9) Paraganglioma–pheochromocytoma | 9 |
| (10) Other rare tumors | 25 |
| PD-L1 status, n (%)* | |
| Positive (H-score >42.5) | 21 (20) |
| Negative (H-score ≤42.5) | 84 (80) |
| Tumor-infiltrating lymphocyte score, n (%)* | |
| 0 | 5 (5) |
| 1 | 47 (45) |
| 2 | 25 (24) |
| 3 | 28 (27) |
*PD-L1 staining and tumor-infiltrating lymphocytes were assessed in 105 baseline tissue samples.
ECOG, Eastern Cooperative Oncology Group; PD-L1, programmed cell death ligand 1.